Adipotide (FTPP)

Adipotide, also referred to as FTPP (a fat-targeting proapoptotic peptide), is an experimental peptide studied in preclinical models for its potential to reduce white adipose tissue. Its design pairs a targeting sequence with a pro-apoptotic element intended to act selectively on the vasculature that supplies fat tissue.

Adipotide is purely experimental. It has never been approved, and there is no established human clinical use. Its profile is defined almost entirely by animal research rather than controlled human trials.

The proposed mechanism is based on animal studies and centres on targeting the blood supply of white fat. High-level themes include:

• A peptide sequence intended to home to receptors associated with the vasculature of white adipose tissue (a prohibitin-targeting approach)
• A linked pro-apoptotic element intended to trigger programmed cell death in those blood vessels
• The idea that disrupting the fat tissue's blood supply could lead to loss of fat mass

This vascular-targeting concept is distinct from metabolic peptides that act on appetite or lipid pathways. How, or whether, such a mechanism could be made safe and effective in humans remains unestablished.

Adipotide is not an approved medicine anywhere and has no recognised clinical indication. Preclinical interest focused on obesity-related endpoints, and the most cited work involved reductions in body weight in obese non-human primates.

Because it remains experimental, adipotide appears only in research discussions and, in some markets, in research-chemical listings. Any framing of it as a weight-loss treatment overstates a body of evidence that has not progressed to established human use.

As a substance not approved for human therapeutic use by any governmental regulatory health authority, adipotide falls under WADA category S0, covering unapproved substances, and would be prohibited at all times for athletes subject to anti-doping rules.

Its experimental status means it has not been the subject of well-known doping cases, but its lack of approval places it clearly within the prohibited category.

A prominent concern raised in the preclinical literature is renal toxicity, with effects on the kidneys observed in animal studies. Because the mechanism involves triggering cell death in targeted vasculature, off-target effects and organ toxicity are central safety questions rather than peripheral ones.

There is no established human safety data, no defined monitoring framework, and no approved formulation. These gaps make any real-world use difficult to evaluate for safety and place adipotide firmly in the experimental category.

Adipotide is described as a targeted peptide construct combining a homing sequence with a pro-apoptotic motif. Its pharmacology is understood mainly through animal models, where distribution to targeted tissue and organ handling are the key variables of interest.

This section describes concepts only. It intentionally does not provide doses, frequencies, or protocols, and it does not constitute medical advice.

In catalogs, adipotide usually appears as a lyophilized powder for reconstitution and is positioned among experimental research peptides. Unlike peptides with body-composition marketing built around appetite or GH pathways, its listing reflects a purely investigational, vascular-targeting concept.

Structural listings in this catalog are organizational and should not be read as endorsements of specific combinations, regimens, or use cases.

Research on adipotide is dominated by preclinical work, most notably studies in obese non-human primates that reported weight loss alongside signals of renal toxicity. This combination generated scientific interest but also underscored the safety hurdles standing between the concept and any human application.

The evidence base has not advanced to established human clinical use, so claims about adipotide as a practical fat-loss agent are not supported. High-level overviews are not a substitute for critical appraisal of the primary preclinical data.

For deeper dives on this peptide, see:

• Adipotide areas of research interest
• Adipotide side effects and safety context
• Adipotide dosing concepts (educational)
• Adipotide research and evidence overview

Future FAQs may cover high-level questions such as how adipotide's vascular-targeting mechanism differs from metabolic weight-loss peptides, why renal-toxicity findings loom so large in its story, what the primate studies did and did not show, and why an experimental preclinical peptide has no established human use. Answers will remain educational and non-prescriptive.